Clinical Trial

90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia

Study acronym: REALM
Recruiting
View on ClinicalTrials.gov →
Summary
This clinical trial will compare 1-year outcomes in patients with hypoalbuminemia and a new diagnosis of small, early-stage hepatocellular carcinoma (HCC) who are candidates for both 90-Yittrium Therasphere transarterial radioembolization (90Y) and microwave ablation (MWA). The study will determine whether treatment with 90Y lowers the risk of disease progression within the first year after diagnosis. Participants will be randomized to receive either first cycle 90Y or MWA and then proceed with standard of care.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-07-12; most recent amendment 2025-07-30.
Status change: Not Yet Recruiting → Recruiting 2023-11-10
Trial Details
NCT Number NCT05953961
Lead Sponsor Ochsner Health System
Collaborators: Boston Scientific Corporation
Conditions Carcinoma, Hepatocellular
Enrollment 50 participants
Start Date 2023-08-08
Primary Completion 2026-08 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-03